To assess the effect of immunological changes and to control subject suffering from hematological malignancies, a careful clinical history of infections, an evaluation of serum immunoglobulins (259) and a quantification of lymphocyte subsets, comprising both CD4, CD8 T cells and B cells are suggested at the diagnosis and after chemotherapy. The gene discussed is CD8A; the disease is hematologic disorder.